


## (Based on the BSSM guidelines, 2017<sup>1)</sup>

# Diagnosing testosterone deficiency



Adapted from Minhas and Mulhall, 20176.

FSH=follicle-stimulating hormone; FT=free testosterone; LH=luteinising hormone; SHBG=sex hormone-binding globulin; TD=testosterone deficiency; TT=total testosterone.



\*For men with TT levels <5.2 nmol/L plus low LH and FSH, or increased prolactin levels, refer to endocrinology

or arrange a pituitary MRI scan to exclude a pituitary adenoma<sup>4,7</sup>.

# Screening

- Screen for TD in men:
- with consistent and multiple signs of TD;
- with ED, loss of spontaneous erections or low sexual desire;
- with T2D, BMI >30 kg/m<sup>2</sup> or WC >102 cm (40.2");
- on long-term opiate, anticonvulsant or antipsychotic medication.

# **History taking**

- Enquire about TD symptoms (e.g. hot flushes, sleep disturbances, muscle loss or strength, changes in mood, cognitive function, sexual function and libido<sup>4</sup>).
- Note previous and current prescription and non-prescription drug use<sup>2</sup>.
- Assess and exclude systemic illness, ongoing acute disease, malabsorption and malnutrition<sup>2.</sup>
- Consider the use of validated guestionnaires (e.g. the ADAM questionnaire, included in the Sexual Advice Association SMART SAA app (http://bit.ly/2EKjTcd), or the AMS Scale (http://bit.ly/2SdtN8C). For information on interpreting the scores, visit http://bit.ly/2OLjUB6.

# **Physical examination**

- Measure height, weight, BMI and WC<sup>8</sup>.
- Look for any gynaecomastia, decreased body hair, loss of height or muscle mass, and abnormalities of the penis, testicles and scrotum<sup>8</sup>.
- Check the prostate via DRE<sup>2</sup>
- Arrange blood investigations, For calculation of FT, including PSA and haematocrit, and appropriate tests based on physical findings and to determine cardiovascular risk.

## About this series

The aim of the "How to" series is to provide readers with a guide to clinical procedures and aspects of diabetes care that are covered in the clinic setting.

## What and why

- Testosterone deficiency (TD) is associated with a variety of physical and psychological effects that can compromise general well-being, sexuality and fertility<sup>2,3</sup>.
- TD is an increasingly common problem, mainly due to increased life expectancy and a greater prevalence of risk factors, including obesity, type 2 diabetes, the metabolic syndrome and a sedentary lifestyle.
- While diagnosing and managing TD can be challenging, it is both feasible and rewarding in primary care.
- To help facilitate this, the BSSM has published a guideline on the diagnosis and management of TD<sup>1</sup>, based on the latest available evidence.

Citation: Kirby M (2018) How to diagnose and manage testosterone deficiency in adult men. Diabetes & Primary Care 20: 169-70

> Laboratory diagnosis Screen for TD in men:

- Measure serum T before 11 a.m., with a reliable method. on at least two separate occasions.
- Obtain fasting levels, where possible.
- an online calculator and app, sponsored by PCTAG, can be found at: http://bit.ly/2q8ralo.

ADAM=androgen deficiency in the ageing male; AMS=ageing males' symptoms; DRE=digital rectal examination; ED=erectile dysfunction; FT=free testosterone; PCTAG=Primary Care Testosterone Advisory Group; PSA=prostate-specific antigen; T=testosterone; T2D=type 2 diabetes; WC=waist circumference.




#### References

- <sup>1</sup>Hackett G, Kirby M, Edwards D et al (2017) The British Society for Sexual Medicine guidelines on adult testosterone deficiency with statements for UK practice. *J Sex Med* **14**: 1504–23
- <sup>2</sup>Dohle GH, Arver S, Bettocchi C et al (2017) *Guidelines on Male Hypogonadism*. European Association of Urology, Arnhem, the Netherlands. Available at: http://bit.ly/2076jTC (accessed 24.10.18)
- <sup>3</sup>British Society of Sexual Medicine (2010) *Guidelines on the Management of Sexual Problems in Men: the Role of Androgens.* BSSM, Lichfield. Available at: http://bit. ly/2xBnKCn (accessed 24.10.18)
- <sup>4</sup>Khera M, Adaikan G, Buvat J et al (2016) Diagnosis and treatment of testosterone deficiency: Recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 13: 1787–804
- <sup>5</sup>International Society for Sexual Medicine (2015) *ISSM Quick Reference Guide on Testosterone Deficiency for Men.* ISSM, Wormerveer, the Netherlands. Available at: http://bit.ly/2R82CuH (accessed 24.10.18)
- <sup>6</sup>Minhas S, Mulhall J (2017) *Male Sexual Dysfunction: A Clinical Guide*. John Wiley, Chichester
- <sup>7</sup>Bhasin S, Cunningham GR, Hayes FJ et al; Task Force, Endocrine Society (2010) Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. *J Clin* Endocrinol Metab **95**: 2536–59
- <sup>8</sup>Lunenfeld B, Mskhalaya G, Zitzmann M et al (2015) Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18: 5–15
- <sup>9</sup>Dean JD, McMahon CG, Guay AT et al (2015) The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men. *J Sex Med* **12**: 1660–86
- <sup>10</sup>Buvat J, Montorsi F, Maggi M et al (2011) Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). *J Sex Med* 8: 284–93
- Icowe G, Bahnson R (2009) Noninvasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. *Ther Adv Urol* 1: 235–42

#### Author

Mike Kirby, Visiting Professor, Faculty of Health and Human Sciences, University of Hertfordshire.



Managing testosterone deficiency

Adapted from Minhas and Mulhall, 20176.

AI=aromatase inhibitor; CVD=cardiovascular disease; DRE=digital rectal examination; HCG=human chorionic gonadotropin; PSA=prostate specific antigen; SERM=selective oestrogen receptor modulator; T=testosterone.

\*These drugs should not be used if pituitary function is compromised. SERMs and AIs are not currently licensed for TD.

## **Testosterone therapy and ED**

- Testosterone therapy is an appropriate treatment for ED<sup>3,9</sup>, particularly when:
  - TT levels are <8 nmol/L<sup>9</sup>
  - oral medications have failed and TT levels are <10.4 nmol/L<sup>10</sup>.
- Testosterone therapy may also reduce the need for more invasive and expensive second- and third-line ED treatments<sup>11</sup>.
- A PDE5i can be prescribed when starting testosterone therapy, in the absence of any contraindications, as it can take many months for testosterone therapy to correct ED.

## Contraindications to testosterone therapy

• The main contraindications include<sup>2</sup>:

- prostate cancer (locally
- advanced or metastatic)
- male breast cancer
- a desire to father children
- haematocrit >54%
- severe chronic heart failure (NYHA class IV).
- An unevaluated prostate nodule or induration, raised PSA, untreated sleep apnoea and severe LUTS may be additional contraindications<sup>7,8</sup>. These conditions should be fully investigated and their management optimised where possible, prior to starting testosterone therapy.

ED=erectile dysfunction; LUTS=lower urinary tract symptoms; NYHA=New York Heart Association; PDE5i=phosphodiesterase type-5 inhibitor; PSA=prostate specific antigen; TT=total testosterone.